Candel Therapeutics, Inc. (CADL)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 6,991 | |||
| General and administrative | 4,186 | |||
| Total operating expenses | 11,177 | |||
| Loss from operations | -11,177 | |||
| Interest expense | 236 | |||
| Interest income | 926 | |||
| Change in fair value of warrant liability | -5,691 | |||
| Total other income (expense), net | 6,381 | |||
| Net income (loss) and comprehensive income (loss) | -4,796 | |||
| Earnings per share, basic | -0.09 | |||
| Earnings per share, diluted | -0.09 | |||
| Weighted average number of shares outstanding, basic | 51,489,929 | |||
| Weighted average number of shares outstanding, diluted | 51,489,929 | |||